A glycolipid-based therapy for glucose homeostasis and TIIDM: α-Galactosylceramide (α-gal-cer), a synthetic glycolipid, increases Pax6 and insulin expression, decreases the levels of glucagon, ghrelin and Somatostatin, reduces metabolic stress, improves insulin sensitivity, promotes glucose homeostasis and prevents progression to TIIDM via down regulation of its target gene, 18/May/2018, 2.03 pm

Introduction: What they say A study from the Department of Developmental Biology and Cancer Research, The Institute for Medical Research Israel-Canada, The Hebrew University-Hadassah Medical School, Jerusalem, Israel shows that “PAX6 maintains ß cell identity by repressing genes of alternative islet cell types.” This research paper was published, in the 12 December 2016 issue of […]

Glycolipid-based Lifespan extension therapy:  α-galactosylceramide (α-GalCer), a synthetic glycolipid, increases life span via up-regulation of its target gene BubR1, 18/May/2018, 1.29 pm

 What they say: Introduction:  A recent study from the Department of Genetics, Paul F. Glenn Laboratories for the Biological Mechanisms of Aging Harvard Medical School, Boston,USA; and Department of Pharmacology, School of Medicine, The University of New South Wales, Australia shows that Sirtuin-2 induces the checkpoint kinase BubR1 to increase lifespan. This study was published, in the 1 July  2014 issue of the […]

Amylin comes to the rescue of autoimmune diabetes: Amylin-based adjunct therapy for autoimmune diabetes (TIDM): Amylin, a 37-residue peptide hormone, increases PD-L1 expression, increases Tregs function, promotes immune tolerance, increases pancreatic β-cell proliferation and regeneration, increases insulin secretion, improves insulin sensitivity, increases energy utilization, and reverses TIDM, via up regulation of its target gene, 18/May/2018, 11.29 am

Introduction: What they say A study from the International Center for T1D, Pediatric Clinical Research Center Romeo ed Enrica Invernizzi, “L. Sacco” Department of Biomedical and Clinical Sciences, University of Milan, Milan 20157, Italy; and Nephrology Division, Boston Children’s Hospital, Harvard Medical School, Boston, MA 02115, USA shows that “PD-L1 genetic overexpression or pharmacological restoration in hematopoietic stem and progenitor […]

Awakening the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Hydrogen-rich saline increases the expression of tumor suppressors genes, such as  p53, TA-p73 and TA-p63, RECK and CADM1, and others, induces regression of p53-mutated human tumors, via down regulation of its target gene, 18/May/2017, 10.45 am

From Significance of the study to Public health relevance:  Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant […]